Edison 
Mito Disease
Team
Clinical Trials
News
Technology
Contact
News
Press Releases
1Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., LtdMarch 28, 20132Edison Pharmaceuticals & Bambino Gesu Children's Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical TrialFebruary 19, 20133Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Friedreich's Ataxia Clinical TrialJanuary 7, 20134Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical TrialNovember 13, 20125Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical TrialSeptember 13, 20126EMA Grants EPI-743 Orphan DesignationSeptember 11, 20127Edison Pharmaceuticals, Inc. closes financingSeptember 13, 20118Edison Pharmaceuticals announces results of EPI-A0001 phase 2A double blind placebo controlled 28-day clinical trial in the mitochondrial disease Friedreich's ataxiaJune 10, 20119Edison Pharmaceuticals to provide expanded access to EPI-743 for mitochondrial diseaseJune 8, 201110Edison Pharmaceuticals announces FDA grants EPI-743 orphan drug designationJune 8, 201111Edison Pharmaceuticals licenses drug from Centocor for rare diseasesJanuary 5, 2010
Edison in the News
1Retina Revealed – Leber's hereditary optic neuropathy case studyJune 23, 20112UMDF - UMDF announces clinical fellowshipJune 17, 20113FARA - EPI-A0001 improves neurological outcome endpoint in 28-Day phase 2A double-blind placebo-controlled clinical trial in Friedreich's ataxiaJune 11, 20114Mitoaction - EPI-743 investigator team to report on Edison mitochondrial drugJune 8, 20115FARA - FDA grants orphan drug designation to EPI-743June 8, 20116EPI-743 UMDF abstractJune 7, 20117EPI-743 AOS abstractJune 7, 20118FARA - Friedreich's ataxia research alliance announces support from NIH RAID pilot programJune 14, 2006
© 2011 Edison Pharmaceuticals, Inc. All rights Reserved.